Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251305 | 0.87 | MEN1 (0.77) | MEN1KMT2ASMN1; SMN2HTTTP53 | |
| SCHEMBL2632919 | 0.73 | MEN1 (0.57) | MEN1KMT2ASMN1; SMN2HTTLMNA | |
| SCHEMBL2070591 | 0.72 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2HTTLMNA | |
| SCHEMBL11243798 | 0.70 | KMT2A (0.54) | MEN1KMT2ASMN1; SMN2HTTLMNA | |
| Methane SCHEMBL11401135 | 0.70 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2HTTLMNA | |
| SCHEMBL5309531 | 0.69 | TP53 (0.63) | HTTTP53 | |
| SCHEMBL2625570 | 0.69 | SMN1; SMN2 (0.65) | MEN1KMT2ASMN1; SMN2HTTLMNA | |
| SCHEMBL16480329 | 0.69 | SMN1; SMN2 (0.59) | MEN1KMT2ASMN1; SMN2HTTLMNA | |
| SCHEMBL220198 | 0.69 | KMT2A (0.51) | MEN1KMT2ASMN1; SMN2HTTLMNA | |
| SCHEMBL3285589 | 0.69 | MEN1 (0.52) | MEN1KMT2AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853276-A2 | COMPOUNDS INHIBITING THE AGGREGATION OF SUPEROXIDE DISMUTASE-1 | The Brighamn and Women's Hospital, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| US-20060194821-A1 | Compounds inhibiting the aggregation of superoxide dismutase-1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-31 | — | — | US | claimed |
| WO-2006089221-A2 | COMPOUNDS INHIBITING THE AGGREGATION OF SUPEROXIDE DISMUTASE-1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-24 | — | — | WO | claimed |
| US-20060194821-A1 | Compounds inhibiting the aggregation of superoxide dismutase-1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194821-A1 | Compounds inhibiting the aggregation of superoxide dismutase-1 | SOD1, SOD3, CAT | MEN1 4454/4885KMT2A 4043/4885SMN1; SMN2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.